Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain.

Cheng Xin / Getty Images Vertex Pharmaceuticals missed first-quarter profit and revenue forecasts as costs jumped. The biotech firm also posted a decline in sales outside the U.S. because of ...

Vertex Pharmaceuticals reported decent Q1 earnings, but the company missed estimates for both revenue and earnings. Vertex's diversification efforts are most visible in the progress of its pain ...

Vertex Pharmaceuticals is pressing pause on a phase 1/2 cystic fibrosis (CF) trial over a tolerability issue while reporting a separate impairment charge of $379 million tied to an earlier ...

Amid a reckoning for the gene therapy field, Vertex Pharmaceuticals has joined a growing list of companies paring back their research efforts around the adeno-associated virus (AAV) vectors used ...

May 5 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab missed Wall Street estimates for quarterly results on Monday due to lower-than-expected sales of its cystic fibrosis (CF ...

Vertex Rail Technologies opened in Wilmington in 2014 with promises of over 1,300 jobs and a $60 million investment. Despite initial optimism and orders, the company faced setbacks including ...

You can reach Jason on Signal at JasonMast.05. Vertex Pharmaceuticals on Monday reported disappointing first-quarter earnings impacted by weaker-than-expected sales of its drugs for cystic ...

For Vertex Pharmaceuticals, the first quarter of 2025 brought good news and bad news. On the bright side, early momentum for newly launched cystic fibrosis (CF) med Alyftrek and pain treatment ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 3% year on year to $2.77 billion. The company’s full-year revenue ...

Vertex Pharmaceuticals reported disappointing Q1 revenue and earnings. The company also revealed it is temporarily pausing part of a phase 1/2 study of experimental cystic fibrosis drug VX-522 ...

Vertex missed Wall Street's Q1 estimates and announced a pause with an early-stage study of its mRNA cystic fibrosis drug. However, the big drugmaker had plenty of good news in its Q1 update, too ...